Proteomics International is a medical technology company at the forefront of predictive diagnostics and bio-analytical services.
Proteomics International has pioneered and launched a world-leading predictive diagnostic test for diabetic kidney disease, PromarkerD, and uses its proprietary PromarkerTM technology platform to create a pipeline of novel diagnostic tests.
From state-of-the-art facilities located in Perth, Western Australia, the company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. The business model is centred on the commercialisation of PromarkerD, with cash burn from R&D and product development offset through provision of specialist analytical services.
Dr Richard Lipscombe – Managing Director
Richard Lipscombe is Founding and Managing Director of Proteomics International Laboratories Ltd [ASX: PIQ].
Dr Lipscombe led the company through its ASX listing in 2015 and now heads the company’s corporate development and the commercialisation of its ground-breaking technologies.
Dr Lipscombe is a protein chemist by training. He completed his chemistry degree at Oxford University and a Doctorate in Immunology at London University. Dr Lipscombe moved to Perth in 1995 and managed the Protein Analysis Facility at the University of Western Australia, before stepping out of academia to co-found Proteomics International in 2001.
What is your rationale for attending 121 Tech Investment?
Profile raising for an under the radar, small cap stock with exceptional global opportunity: enormous market, de-risked clinically, commercial ready, revenue generating.
What recent news would you like to highlight to investors attending?
Nov 2018 Proteomics signs PromarkerD agreement with US big pharma
Feb 2019 US patent for identifying drugs for abnormal kidney function
Apr 2019 Proteomics to present at BIO and American Diabetes Association in June
What are your key goals for the next 3, 6 and 12 months?
Launch of PromarkerD test in new jurisdictions
New licensing deals for PromarkerD | Growing revenue from sales of PromarkerD | Launch of PromarkerD test in new jurisdictions
Development of novel diagnostic tests in areas of significant unmet medical need| Growing revenue from sales of PromarkerD | New licensing deals for PromarkerD | Launch of PromarkerD test in new jurisdictions
What do you see as the key risks and challenges facing your company at the moment and how are you overcoming these?
Adoption of novel technology is slow is clinical practice – Proteomics International is engaged with Key Opinion Leaders to drive adoption of its ground-breaking diagnostic test
What do you think makes your company such a compelling investment?
Enormous market, de-risked clinically, commercial ready, revenue generating